About NantHealth (NASDAQ:NH)
NantHealth, Inc. is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient's tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples. The Company also offers Nant Operating System (NantOS) and NantOS applications to healthcare providers and payors, self-insured employers and biopharmaceutical companies. It offers CLINICS, an integrated solution that includes GPS Cancer, NantOS and the NantOS applications. The CLINICS solution includes System Infrastructure, Knowledge Platform, Provider Platform and Payor Platform.
Industry, Sector and Symbol
Industry Data processing & preparation
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NH
CUSIPN/A
Phone310-883-1300
Debt
Debt-to-Equity Ratio1.01%
Current Ratio2.28%
Quick Ratio2.26%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$86.68 million
Price / Sales4.20
Cash FlowN/A
Price / CashN/A
Book Value$1.78 per share
Price / Book1.88
Profitability
EPS (Most Recent Fiscal Year)($1.12)
Net Income$-175,210,000.00
Net Margins-188.81%
Return on Equity-54.16%
Return on Assets-27.35%
Miscellaneous
Employees494
Outstanding Shares108,580,000
NantHealth (NASDAQ:NH) Frequently Asked Questions
What is NantHealth's stock symbol?
NantHealth trades on the NASDAQ under the ticker symbol "NH."
How were NantHealth's earnings last quarter?
NantHealth Inc (NASDAQ:NH) posted its quarterly earnings data on Wednesday, March, 14th. The company reported ($0.21) EPS for the quarter. The company had revenue of $22.30 million for the quarter, compared to analyst estimates of $23.50 million. NantHealth had a negative net margin of 188.81% and a negative return on equity of 54.16%. View NantHealth's Earnings History.
When is NantHealth's next earnings date?
What price target have analysts set for NH?
3 brokerages have issued 12-month target prices for NantHealth's shares. Their predictions range from $4.50 to $5.00. On average, they expect NantHealth's stock price to reach $4.8333 in the next twelve months. View Analyst Ratings for NantHealth.
Who are some of NantHealth's key competitors?
Some companies that are related to NantHealth include Sohu (SOHU), Evertec (EVTC), Yext (YEXT), Carbonite (CARB), Liberty TripAdvisor (LTRPA), Renren (RENN), Computer Services (CSVI), Tucows (TCX), Castlight Health (CSLT), FRONTEO (FTEO), Veritone (VERI), ZIX (ZIXI), Brightcove (BCOV), Ooma (OOMA) and Park City Group (PCYG).
Who are NantHealth's key executives?
NantHealth's management team includes the folowing people:
- Patrick Soon-Shiong M.D., Chairman of the Board, Chief Executive Officer, Founder (Age 64)
- Paul A. Holt, Chief Financial Officer (Age 50)
- Michael D. Blaszyk, Independent Director (Age 64)
- Mark Burnett, Independent Director (Age 56)
- Kirk K. Calhoun, Independent Director (Age 73)
- Michael S. Sitrick, Independent Director (Age 69)
When did NantHealth IPO?
(NH) raised $91 million in an IPO on Thursday, June 2nd 2016. The company issued 6,500,000 shares at $12.50-$15.50 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and First Analysis Securities, Canaccord Genuity and FBR were co-managers.
Has NantHealth been receiving favorable news coverage?
Media stories about NH stock have been trending somewhat positive on Tuesday, according to Accern Sentiment. Accern scores the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. NantHealth earned a media sentiment score of 0.08 on Accern's scale. They also assigned press coverage about the company an impact score of 46.25 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of NantHealth?
Shares of NH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NantHealth's stock price today?
One share of NH stock can currently be purchased for approximately $3.35.
How big of a company is NantHealth?
NantHealth has a market capitalization of $359.40 million and generates $86.68 million in revenue each year. The company earns $-175,210,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. NantHealth employs 494 workers across the globe.
How can I contact NantHealth?
NantHealth's mailing address is 9920 JEFFERSON BLVD, CULVER CITY CA, 90232. The company can be reached via phone at 310-883-1300 or via email at [email protected]
MarketBeat Community Rating for NantHealth (NH)
MarketBeat's community ratings are surveys of what our community members think about NantHealth and other stocks. Vote "Outperform" if you believe NH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NH will underperform the S&P 500 over the long term. You may vote once every thirty days.
NantHealth (NASDAQ:NH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for NantHealth in the last 12 months. Their average twelve-month price target is $4.8333, suggesting that the stock has a possible upside of 44.28%. The high price target for NH is $5.00 and the low price target for NH is $4.50. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.8333 | $8.10 | $9.00 | $9.25 |
| Price Target Upside: | 44.28% upside | 167.33% upside | 152.81% upside | 105.56% upside |
NantHealth (NASDAQ:NH) Consensus Price Target History
NantHealth (NASDAQ:NH) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
NantHealth (NASDAQ:NH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
NantHealth (NASDAQ NH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 58.00%
Institutional Ownership Percentage: 6.25%
NantHealth (NASDAQ NH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/6/2018 | Ronald Allen Louks | COO | Sell | 7,005 | $3.04 | $21,295.20 | 89,690 |  |
| 3/6/2018 | Ronald Allen Louks | COO | Sell | 7,095 | $3.56 | $25,258.20 | 89,690 | |
| 2/6/2018 | Ronald Allen Louks | COO | Sell | 6,475 | $3.02 | $19,554.50 | 89,690 | |
| 1/8/2018 | Ronald Allen Louks | COO | Sell | 6,175 | $3.52 | $21,736.00 | 89,690 | |
| 12/6/2017 | Ronald Allen Louks | COO | Sell | 5,245 | $3.03 | $15,892.35 | 89,690 | |
| 11/6/2017 | Ronald Allen Louks | COO | Sell | 6,705 | $3.39 | $22,729.95 | 10,000 | |
| 10/6/2017 | Ronald Allen Louks | COO | Sell | 26,820 | $4.28 | $114,789.60 | | |
| 6/7/2016 | Healthcare Solution Allscripts | Major Shareholder | Buy | 714,286 | $14.00 | $10,000,004.00 | 15,000,000 | |
| 6/7/2016 | Patrick Soon-Shiong | CEO | Buy | 357,143 | $14.00 | $5,000,002.00 | | |
(Data available from 1/1/2013 forward)
NantHealth (NASDAQ NH) News Headlines
| Source: |
|
NantHealth (NASDAQ:NH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
NantHealth (NASDAQ:NH) Income Statement, Balance Sheet and Cash Flow Statement
NantHealth (NASDAQ NH) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
